Generic Drug

The FDA approved a generic version of the GLP-1 receptor agonist liraglutide to improve glycemic control for people with type 2 diabetes, according to a press release from the agency.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

A 90-day supply of most of the top generic drugs in the U.S. can be purchased from a discount program for $15 or less, but none of the programs consistently offer the lowest prices for generic drugs, according to two presenters.

Teva Pharmaceuticals announced it has launched the first generic version of a GLP-1 receptor agonist in the United States, liraglutide 1.8 mg.

The FDA has approved an abbreviated new drug application for a generic version of Emflaza to treat Duchenne muscular dystrophy, according to the manufacturer.

The Mark Cuban Cost Plus Drug Company launched in January 2022 to a flurry of promises, curiosity, and a certain guarded optimism among experts regarding its potential to lower medication prices for patients.

The FDA has approved an abbreviated new drug application for Lupin Limited’s generic febuxostat 40 mg and 80 mg tablets, according to a press release from the manufacturer.

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.

Neurocrine Biosciences has announced the resolution of litigation resulting from abbreviated new drug applications brought by companies that wished to market a generic version of Ingrezza before its patent expires.

The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.